BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[OncoGenex (OGXI): Biotech Targets Cancer Treatments]]>http://www.bloggingstocks.com/2011/04/06/oncogenex-ogxi-biotech-targets-cancer/http://www.bloggingstocks.com/2011/04/06/oncogenex-ogxi-biotech-targets-cancer/http://www.bloggingstocks.com/2011/04/06/oncogenex-ogxi-biotech-targets-cancer/#commentsFiled under: , ,

"OncoGenex Pharmaceuticals (OGXI) recently released their fourth quarter and year end 2010 financial results; during the conference call they discussed updates in their development programs and provided an outlook for 2011," notes biotech specialist John McCamant.

The editor of the Medical Technology Stock Letter continues, "The company reported a Q4 2010 net loss of $2.8 million or ($0.26) per share compared to Q4 2009 net profit of $3.9 million or $0.70 per share.

"OGXI finished the year in a solid position financially with $85.6 million in cash. The company expects to end 2011 with $50-$54 million on the balance sheet and use $31-$35 million in operating cash. They appear to have enough cash to fund operations into 2014.

Continue reading OncoGenex (OGXI): Biotech Targets Cancer Treatments

OncoGenex (OGXI): Biotech Targets Cancer Treatments originally appeared on BloggingStocks on Wed, 06 Apr 2011 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnology stocksBiotechnologyStocksbladder cancer treatment stocksCancerTreatmentStocksfeaturedjohn mccamantJohnMccamantlung cancer treatment stocksmedical technology stock letterOGXIOncoGenexoncology stocksprostate cancer treatment stockssteven halpernthestockadvisors.comWed, 06 Apr 2011 10:00:00 EST<![CDATA[Novartis (NVS): Big Pharma's best pipeline]]>http://www.bloggingstocks.com/2008/07/07/novartis-nvs-big-pharmas-best-pipeline/http://www.bloggingstocks.com/2008/07/07/novartis-nvs-big-pharmas-best-pipeline/http://www.bloggingstocks.com/2008/07/07/novartis-nvs-big-pharmas-best-pipeline/#commentsFiled under: , , ,

"The pipelines of most Big Pharmas are bone dry; last year, the FDA approved the lowest number of new drugs (19) since 1983," notes Louis Basenese, editor of The Oxford Club.

"But opportunity always lurks in the wreckage, and one Big Pharma, in particular, is being unfairly punished." Here's his bullish outlook on Novartis (NYSE: NVS).

"Unlike others in the sector, Novartis doesn't suffer from an empty pipeline. It's launched more drugs globally than any other firm in the past seven years. It has more than 100 projects in phase II (or later) trials. And it expects to file at least six new drug applications this year alone.

"Plus, its products cover all bases, from vaccines to specialized drugs to generics to eye-care products, even animal health items. And most are enjoying rapidly expanding sales.

"Moreover, the company maintains a fortress-like financial position that includes a $10.8 billion cash horde. Management keeps raising the dividend, for 11 years and counting. And it recently announced a massive $9 billion stock-repurchase plan, too. Hardly the hallmarks of a sickly stock.

Continue reading Novartis (NVS): Big Pharma's best pipeline

Novartis (NVS): Big Pharma's best pipeline originally appeared on BloggingStocks on Mon, 07 Jul 2008 11:22:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>antibiotics stocksAntibioticsStocksbig pharmaBigPharmadrug stocksDrugStockshealthcare stockslouis baseneseLouisBasenesenovartisoncology stocksOncologyStockspharmaceutical stocksthe oxford clubTheOxfordClubthestockadvisors.comMon, 07 Jul 2008 11:22:00 EST